Fucoidan Protects Dopaminergic Neurons by Enhancing the Mitochondrial
Fucoidan Protects Dopaminergic Neurons by Enhancing the Mitochondrial Function in a Rotenone-induced Rat Model of Parkinson&#x 02019; s Disease Zhang Li, Hao Junwei, Zheng Yan, Su Ruijun, Liao Yajin, Gong Xiaoli, Liu Limin, Wang Xiaomin 1 Department of Neurobiology, 2 Department of Physiology, 3 Key Laboratory for Neurodegenerative Disorders of the Ministry of Education, Capital Medical University, Beijing 100069, China. 4 The Brain Science Center, Beijing Institute of Basic Medical Sciences, Beijing 100039, China. 5 Beijing Institute for Brain Disorders, Beijing 100069, China Figure 5 Effects of fucoidan on contents of striatal DA and its metabolites ( A-C ) Effects of fucoidan on striatal DA, DOPAC, and HVA levels. ( D ) Effects of fucoidan on the ratio of DOPAC + HVA to DA. The contents of DA, DOPAC, and HVA in the striatum were measured by HPLC. Note that fucoidan reversed a decrease in DA and DOPAC levels and an increase in the ratio of DOPAC + HVA to DA induced by rotenone. The difference of DA Aging and Disease, 2018, 9(4), 590 -604. DOI: 10. 14336/AD. 2017. 0831 turnover rate between the 140 mg/kg fucoidan group and 0. 3 mg/kg rasagiline group was significant. Data are shown as means &#x 000 B 1; SEM (n = 3 -5 per group). &#x 0002 A; P &#x 0003 C; 0. 05 versus vehicle group. # P &#x 0003 C; 0. 05, ## P &#x 0003 C; 0. 01, and ### P &#x 0003 C; 0. 001 versus model group (rotenone only). &#x 00026; P &#x 0003 C; 0. 01 versus rasagiline group.
- Slides: 1